These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 27491481

  • 1. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
    Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB.
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):685-95. PubMed ID: 27491481
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P.
    J Clin Oncol; 2014 Apr 01; 32(10):1050-7. PubMed ID: 24590635
    [Abstract] [Full Text] [Related]

  • 3. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
    Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC.
    J Clin Oncol; 2013 May 10; 31(14):1726-31. PubMed ID: 23569315
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W, Deng H, Rao N, You N, Yang Y, Cao M, Liu J.
    Trials; 2017 Oct 25; 18(1):497. PubMed ID: 29070044
    [Abstract] [Full Text] [Related]

  • 5. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S.
    Clin Cancer Res; 2014 Feb 01; 20(3):736-43. PubMed ID: 24198242
    [Abstract] [Full Text] [Related]

  • 6. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E.
    Lancet Oncol; 2019 Sep 20; 20(9):1226-1238. PubMed ID: 31402321
    [Abstract] [Full Text] [Related]

  • 12. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
    Skriver SK, Jensen MB, Knoop AS, Ejlertsen B, Laenkholm AV.
    Breast Cancer Res; 2020 May 14; 22(1):46. PubMed ID: 32410705
    [Abstract] [Full Text] [Related]

  • 13. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
    Curran MP.
    Drugs; 2010 Jul 30; 70(11):1411-22. PubMed ID: 20614948
    [Abstract] [Full Text] [Related]

  • 14. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
    Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S.
    Oncologist; 2010 Jul 30; 15(2):122-9. PubMed ID: 20156908
    [Abstract] [Full Text] [Related]

  • 15. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW.
    Curr Med Res Opin; 2012 Aug 30; 28(8):1263-79. PubMed ID: 22738819
    [Abstract] [Full Text] [Related]

  • 16. Letrozole in the neoadjuvant setting: the P024 trial.
    Ellis MJ, Ma C.
    Breast Cancer Res Treat; 2007 Aug 30; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
    [Abstract] [Full Text] [Related]

  • 17. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
    Wu W, Chen J, Deng H, Jin L, He Z, Rao N, Nie Y, Yao Y, Yang Y, Su F, Liu J.
    BMC Cancer; 2021 Jul 27; 21(1):862. PubMed ID: 34315439
    [Abstract] [Full Text] [Related]

  • 18. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.
    J Clin Oncol; 2009 Jun 01; 27(16):2630-7. PubMed ID: 19380449
    [Abstract] [Full Text] [Related]

  • 19. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M.
    J Clin Oncol; 2001 Sep 15; 19(18):3808-16. PubMed ID: 11559718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.